Literature DB >> 1752786

Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6.

K Takeda1, N Fujii, Y Nitta, H Sakihara, K Nakayama, H Rikiishi, K Kumagai.   

Abstract

Increasing evidence suggests that an intimate correlation may exist between the production of a cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF) and the ability to metastasize spontaneously in the lungs in murine transplantable tumors. In the present study, we further examined the cytokine production by tumor cells with the ability to metastasize in the liver. Four out of 8 test tumors, which produced metastasis in the lungs but not in the liver, exhibited the ability to produce GM-CSF activity in culture. Three other tumors produced metastasis in the liver but not in the lungs. These tumor cells exhibited no ability to produce GM-CSF, but two of them expressed an interleukin-6 (IL-6) mRNA and also produced IL-6 activity in the culture fluids. One of the two IL-6-producing tumors and the remaining liver metastatic tumor produced interleukin-1 (IL-1) as revealed by bioassay and neutralization test. In the tumor cells producing pulmonary metastasis, neither IL-6 gene expression nor IL-1 production could be detected. The last test tumor, which produced no metastasis either in the lungs or liver, produced neither GM-CSF, IL-1 nor IL-6. Furthermore, injection of antisera reactive to recombinant murine IL-6 caused a marked decrease of the number of liver metastases of an IL-6-producing tumor, but not lung metastases of a GM-CSF-producing tumor, which could be markedly inhibited by injection of anti-recombinant murine GM-CSF sera. These results suggest the possibility that there may be a correlation between the cytokines produced by tumor cells and their organ specificity in spontaneous metastasis, and also indicate that these tumor models may provide a useful tool for studies on the role of cytokines in tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752786      PMCID: PMC5918332          DOI: 10.1111/j.1349-7006.1991.tb01796.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


colony‐stimulating factor granulocyte/macrophage CSF interleukin‐1 inter‐leukin‐6 recombinant murine GM‐CSF or IL‐6 recombinant murine or human IL‐1 cycloheximide
  41 in total

Review 1.  Autocrine growth factors and tumourigenic transformation.

Authors:  R A Lang; A W Burgess
Journal:  Immunol Today       Date:  1990-07

2.  Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells.

Authors:  Y Tsuchiya; M Igarashi; R Suzuki; K Kumagai
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

3.  Are colony-stimulating factor-producing cells facilitated in the metastatic process?

Authors:  G Nicoletti; P L Lollini; G P Bagnara; C De Giovanni; B Del Re; L Bons; G Prodi; P Nanni
Journal:  Anticancer Res       Date:  1987 Jul-Aug       Impact factor: 2.480

4.  Repair of potentially lethal radiation damage in acute and chronically hypoxic tumor cells in vivo.

Authors:  M Urano; N Nesumi; K Ando; S Koike; N Ohnuma
Journal:  Radiology       Date:  1976-02       Impact factor: 11.105

5.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

6.  Distribution of IL-5 receptor-positive B cells. Expression of IL-5 receptor on Ly-1(CD5)+ B cells.

Authors:  Y Hitoshi; N Yamaguchi; S Mita; E Sonoda; S Takaki; A Tominaga; K Takatsu
Journal:  J Immunol       Date:  1990-06-01       Impact factor: 5.422

7.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.

Authors:  H Nakajima; H Fujiwara; Y Takai; Y Izumi; S Sano; T Tsuchida; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

8.  A correlation between GM-CSF gene expression and metastases in murine tumors.

Authors:  K Takeda; K Hatakeyama; Y Tsuchiya; H Rikiishi; K Kumagai
Journal:  Int J Cancer       Date:  1991-02-01       Impact factor: 7.396

9.  Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.

Authors:  C B Siegall; G Schwab; R P Nordan; D J FitzGerald; I Pastan
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 13.312

10.  Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro.

Authors:  G J Darlington; D R Wilson; L B Lachman
Journal:  J Cell Biol       Date:  1986-09       Impact factor: 10.539

View more
  14 in total

1.  Effect of IL-6 on tumor cell invasion of vascular endothelial monolayers.

Authors:  Y Kitamura; I Morita; Z Nihei; Y Mishima; S Murota
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  Interleukin-12 induces cytotoxic NK1+ alpha beta T cells in the lungs of euthymic and athymic mice.

Authors:  R Anzai; S Seki; K Ogasawara; W Hashimoto; K Sugiura; M Sato; K Kumagai; K Takeda
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

3.  IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls.

Authors:  Bin Xu; Xiao-Bing Niu; Zi-Dun Wang; Wei Cheng; Na Tong; Yuan-Yuan Mi; Zhi-Chao Min; Jun Tao; Peng-Chao Li; Wei Zhang; Hong-Fei Wu; Zheng-Dong Zhang; Zeng-Jun Wang; Li-Xin Hua; Ning-Han Feng; Xin-Ru Wang
Journal:  Mol Biol Rep       Date:  2010-11-23       Impact factor: 2.316

4.  Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker.

Authors:  J S Goydos; A M Brumfield; E Frezza; A Booth; M T Lotze; S E Carty
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

5.  Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Dig Dis Sci       Date:  2008-07-26       Impact factor: 3.199

6.  Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells.

Authors:  Nathalie Scamuffa; Geraldine Siegfried; Yannick Bontemps; Liming Ma; Ajoy Basak; Ghislaine Cherel; Fabien Calvo; Nabil G Seidah; Abdel-Majid Khatib
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

7.  Role of SPan-1 antigen in adhesion of human colon cancer cells to vascular endothelium.

Authors:  N Yamada; Y S Chung; T Sawada; M Okuno; M Sowa
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

8.  Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis.

Authors:  T Ueda; E Shimada; T Urakawa
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

9.  Morphine attenuates endothelial cell adhesion molecules induced by the supernatant of LPS-stimulated colon cancer cells.

Authors:  Too Jae Min; Sang-Hee Park; Yi-Hwa Ji; Yoon-Sook Lee; Tae Woo Kim; Jae Hwan Kim; Woon-Young Kim; Young-Cheol Park
Journal:  J Korean Med Sci       Date:  2011-05-18       Impact factor: 2.153

10.  Increased sialyl Lewis A expression and fucosyltransferase activity with acquisition of a high metastatic capacity in a colon cancer cell line.

Authors:  N Yamada; Y S Chung; S Takatsuka; Y Arimoto; T Sawada; T Dohi; M Sowa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.